Recent

% | $
Quotes you view appear here for quick access.

International Stem Cell Corporation Message Board

btimnextmicrosoft 84 posts  |  Last Activity: Apr 29, 2015 4:27 PM Member since: Oct 15, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Biotimes ip domination of hESC will be huge now that the tide for both research AND therapeutics is turning from IPS cells to human embryonic stem cells. All three recent partners committing to our patented hESC platform.
    Next-gen biotech big pharma comin up!

  • Everyone but Michael West. Biotime has spent the last eight years acquiring the worlds majority of GMP hESC lines. Dr. West was one of the few that had the guts and smarts, all the rest played it safe running from the right wing religious yahoos. Now Biotime reaping the rewards with a monopoly of hESC ip and partnerships coming now just about every month.

    Sentiment: Strong Buy

  • Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world's understanding of how biology affects diseases such as diabetes, HIV/AIDS, and cancer.

  • btimnextmicrosoft btimnextmicrosoft Apr 22, 2015 9:04 PM Flag

    Heads, let's get to $10 before contemplating $100!....all in good time.

    Btw our new partner is no small potatoes:
    Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world's understanding of how biology affects diseases such as diabetes, HIV/AIDS, and cancer.

  • btimnextmicrosoft btimnextmicrosoft Apr 22, 2015 9:01 PM Flag

    ...with that said, all the more reason to invest in BTX while they are in the 'embryonic' stage.

  • btimnextmicrosoft btimnextmicrosoft Apr 22, 2015 8:58 PM Flag

    Phil, BTX has six other subsidiaries besides AST, not all will IPO. A few likely will including OncoCyte, OrthoCyte and ReCyte.
    OrthoCyte long term will have 12 different kinds of 'off the shelf' cartilage progenitors for transplant. Clinical trial phase one results for knee cartilage regen will be out within three months. These hESC progenitors are combined with their extra-cellular matrix product called HyStem. Expect an OrthoCyte IPO in 2016 after it is clear these cartilage/ECM products work. Chances are they do since animal preclinical studies were very promising.
    OncoCyte will have bladder and breast cancer diagnostic products starting to hit the market end of 2015, with breast PanC-DX soon to follow. They also have nano-peptide anti-tumor ip that will start clinical trials likely by years end. Expect a OncoCyte IPO in late 2015 before revenues from PanC-DX start pouring in.
    ReCtye will have cardio, vascular and blood regen therapies entering clinical studies in 2016, so expect a late 2016/17 IPO unless they decide to take the world on by storm with a ACTC merger which is looking less likely last couple years.

  • Picks & shovels for tomorrow's gold mine:
    ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 22, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime's subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the City of Hope (BRICOH, Duarte, CA) through which ESI's clinical-grade human embryonic stem (hES) cells will be manufactured and provided to BRICOH's clinical collaborators, including medical research organizations intent on using the hES cells to develop and commercialize therapeutic products to treat human disease. The Agreement is a critical part of BioTime's strategy to leverage third party funding and generate future revenues by placing its hES cells in programs developing a wide array of therapeutic applications made possible with pluripotent stem cell technology, products that are currently not being developed by BioTime or its subsidiaries. Successful medical research organizations will need to obtain separate licenses from BioTime in order to advance their products based on ESI's hES cells into clinical trials and commercialization. Those licenses may entitle BioTime to receive additional revenues such as milestone payments related to the attainment of clinical trial and commercial milestones and royalties on product sales. BioTime and BioTime subsidiaries will retain the rights to manufacture their own stem cell-based products as well as to license rights to other third parties.

  • Reply to

    going up After Hours! 5,55 +1,82%

    by rios.facundo Apr 21, 2015 6:42 PM
    btimnextmicrosoft btimnextmicrosoft Apr 21, 2015 8:21 PM Flag

    Get in while we are still under $20....Gold mine!

  • Reply to

    ReCyte

    by twicesilent23 Apr 21, 2015 4:33 PM
    btimnextmicrosoft btimnextmicrosoft Apr 21, 2015 5:10 PM Flag

    A couple days ago:
    A poster, including an abstract of the results of work by BioTime scientists with human embryonic stem cell-derived clonal brown adipocyte progenitors, presented by BioTime at the Keystone Symposia on Molecular and Cellular Biology.

  • Reply to

    OncoCyte IPO next

    by ipstissueface Apr 20, 2015 6:39 PM
    btimnextmicrosoft btimnextmicrosoft Apr 21, 2015 12:46 AM Flag

    Im ready to invest in the next subsidiary, bring it on! BTX is smart for introducing these subsidiaries early on before BTX grows, if BTX was a $100 there would be no need for this. Great way to expand the BTX brand!

  • btimnextmicrosoft by btimnextmicrosoft Apr 20, 2015 11:27 PM Flag

    Our ips cell competitor Cellular Dynamics(ips) has sold to fujifilm for 300mil. It's a lot, then again it's not. It's not a lot because ips cells will eventually be the future of regen medicine they say.....and it's a lot because ICEL I think basically abandoned ship. Why do I say this, a few reasons, 1) GE who signed a true testing deal a year or so ago with ICEL called it quits and recently sided with drug testing on 'the gold standard'(Biotimes hESC's).
    2)ICEL's stock price a month or so ago took a huge nose dive. 3) ICEL's CEO Jamie Thompson is one of the leadeing minds working with IPS cells and for him to sell the company for 300 MIL means ips cells are a long way off and maybe his bank of immune matching ips cells had less of a chance then previously thought for being the future cell solution.
    With that said 300mil all in all is a lot but when you look at their 800+ ips cell ip you would think it to be a bit short of expectation.

  • btimnextmicrosoft by btimnextmicrosoft Apr 20, 2015 1:09 PM Flag

    Looking forward to Biotime's OncoCyte to go public in 2016 after anti-tumor therapy starts clinical trial and massive revs start coming in from PanCDX.

  • Breast cancer PanC-DX to be inertial part of next-gen cancer diagnostics. Very exciting news, mammograms will still be used but PanC-DX will be the first and most accurate test for millions of patients. Big money! Breast Panc-DX to be on the market as early as late 2015 as well as bladder PanC. Lung PanC in early 2016.

    Title: OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers

    Date(s): 20-Apr-2015 12:01 PM
    Data Presented at American Association for Cancer Research 2015 Annual Meeting

    ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 20, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced initial data from a large, prospective clinical study that showed the potential of PanC-DxTM, OncoCyte's non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The clinical data was presented by Maria Prendes, PhD, Director of Manufacturing at OncoCyte, at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 8:00 AM -12:00 PM EDT on Monday, April 20, 2015.

  • Reply to

    Why this stock will never hit $100. Or $10.

    by realtruf Apr 17, 2015 10:36 AM
    btimnextmicrosoft btimnextmicrosoft Apr 17, 2015 10:08 PM Flag

    Realtruf and baltbear same I'd, this guy has been bashing and buying since 2007 when BTX was 0.40. By years end BTX will have cancer diagnostic products being used in major hospitals and stock will be over $12 and climbing. Hopefully these parasites will move on to other smaller, more volatile stocks.

  • Here are just a few of the products due out on the market over next 6 mo to 2 yrs:
    -LifeMap COPD/asthma medical apps(out now, more to follow)
    -GE/BTX drug testing kits
    -Adipose/ECM Cosmetic surgery products(EU)
    -PanC-DX bladder, lung, breast cancer diagnostic products(6 mo release date)
    -Cartilage/ECM (clinical trials)
    -AMD retinal cell therapy(clinical trials)

  • Reply to

    BTX/GE deal

    by headsupeyesclosed Apr 2, 2015 5:35 PM
    btimnextmicrosoft btimnextmicrosoft Apr 17, 2015 12:04 PM Flag

    BTX has a monopoly on hESC, so our family of research products will be unmatched

  • Might want to buy, things are going to start heating up

  • Reply to

    Sold My NWBO for more BTX

    by colinelbasani Apr 16, 2015 2:04 PM
    btimnextmicrosoft btimnextmicrosoft Apr 16, 2015 10:01 PM Flag

    Smart move. $100 is not out of the question within two or three years time.

  • Reply to

    BTX

    by short_buster Apr 16, 2015 11:50 AM
    btimnextmicrosoft btimnextmicrosoft Apr 16, 2015 1:00 PM Flag

    Only a matter of time before Biotime is way higher then AST. In the mean time Dr. Wests plan to acquire Geron ip and build Cancer regen empire has proved successful.
    Cosmetic regen surgery products hit the market in EU by years end as well as PanC-DX product line.
    Top stem cell play hands down. Mad Money's Cramer will be hitting the BUY-BUY-BUY button on this one early next year when we are at $18 and climbing.

  • btimnextmicrosoft by btimnextmicrosoft Apr 15, 2015 4:32 PM Flag

    BTX on the way to revolutionizing the field of Oncology

ISCO
0.0595+0.0012(+2.06%)May 4 3:47 PMEDT